CEF19, Epstein-Barr Virus latent NA-3A (458-466) – 1 mg

Overview

CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a highly specific HLA-B35-restricted epitope derived from the Epstein-Barr Virus latent nuclear antigen 3A. This peptide plays a critical role in the immune response to Epstein-Barr Virus (EBV) infection, making it a valuable tool for research in virology and immunology. As you explore options for your research or diagnostic needs, consider the quality and specificity of CEF19. Available for purchase now, this peptide is ideal for studies focused on EBV’s role in various diseases, including autoimmune disorders and certain cancers.

Key Features

• Highly specific HLA-B35-restricted epitope
• Derived from Epstein-Barr Virus latent nuclear antigen 3A
• Supports research in virology and immunology
• Well-characterized for reliable results

Specifications

FAQ

What applications can CEF19 be used for?

CEF19 can be used in various research applications, including T cell epitope mapping, vaccine development, and studies examining the immune response to Epstein-Barr Virus.

How is CEF19 synthesized?

This peptide is synthesized using solid-phase peptide synthesis (SPPS) techniques, ensuring high purity and reliability for your experiments.

Is CEF19 suitable for in vivo studies?

While CEF19 is primarily designed for in vitro research applications, consult your lab protocols or check with our experts for its use in in vivo studies.

For related research tools, explore our PKG Substrate or check out Autocamtide-2 for further insights into proteomic research. Also, discover our complete selection of peptides to support your ongoing studies.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled